Inari Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.7 Mil. Inari Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $30.4 Mil. Inari Medical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $464.9 Mil.
Inari Medical's debt to equity for the quarter that ended in Dec. 2023 was 0.07.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Inari Medical's Debt-to-Equity or its related term are showing as below:
NARI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.5 Med: 0.07 Max: 0.12
Current: 0.07
During the past 6 years, the highest Debt-to-Equity Ratio of Inari Medical was 0.12. The lowest was -0.50. And the median was 0.07.
Inari Medical Debt-to-Equity Historical Data
The historical data trend for Inari Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Inari Medical Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
-0.50 |
- |
0.12 |
0.08 |
0.07 |
|
Inari Medical Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.08 |
0.08 |
0.08 |
0.07 |
0.07 |
Competitive Comparison
For the Medical Devices subindustry, Inari Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inari Medical Debt-to-Equity Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Inari Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Inari Medical's Debt-to-Equity falls into.
Inari Medical Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Inari Medical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Inari Medical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inari Medical (Inari Medical) Business Description
Traded in Other Exchanges
Address
6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.
Executives
| William Hoffman |
director, officer: President and CEO |
C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
| Mitch C. Hill, |
officer: Chief Financial Officer |
1009 TENNYSON DRIVE, SOUTHLAKE TX 76902 |
| Andrew Hykes |
officer: Chief Operating Officer |
C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618 |
| Thomas Tu |
officer: Chief Medical Officer |
C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618 |
| Donald B Milder |
director |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Robert Keith Warner |
director |
C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
| Catherine M. Szyman |
director |
C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614 |
| Cynthia L Lucchese |
director |
7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260 |
| Mead Dana G Jr. |
director |
2750 SAND HILL ROAD, MENLO PARK CA 94025 |
| Rebecca Chambers |
director |
3052 ORCHARD DR., SAN JOSE CA 95134 |
| Jonathan D Root |
director |
2735 SAND HILL ROAD, MENLO PARK CA 94025 |
| Cooperatieve Gilde Healthcare Iv U.a. |
10 percent owner |
NEWTONLANN 51, UTRECHT P7 3508AB |
| Kirk G. Nielsen |
director, 10 percent owner |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Gilde Healthcare Iv Management B.v. |
10 percent owner |
NEWTONLAAN 91, UTRECHT P7 3584 BP |
| Gilde Healthcare Holding B.v. |
10 percent owner |
NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB |
Inari Medical (Inari Medical) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NARI has been successfully added to your